Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) FCF Margin (2023 - 2025)

Iovance Biotherapeutics has reported FCF Margin over the past 4 years, most recently at 71.37% for Q4 2025.

  • Quarterly results put FCF Margin at 71.37% for Q4 2025, up 3375.0% from a year ago — trailing twelve months through Dec 2025 was 127.61% (up 9428.0% YoY), and the annual figure for FY2025 was 127.61%, up 9428.0%.
  • FCF Margin for Q4 2025 was 71.37% at Iovance Biotherapeutics, up from 132.69% in the prior quarter.
  • Over the last five years, FCF Margin for IOVA hit a ceiling of 71.37% in Q4 2025 and a floor of 42587.82% in Q2 2023.
  • Median FCF Margin over the past 3 years was 222.82% (2025), compared with a mean of 8926.97%.
  • Biggest five-year swings in FCF Margin: soared 4226996bps in 2024 and later plummeted -2806bps in 2025.
  • Iovance Biotherapeutics' FCF Margin stood at 18153.32% in 2023, then skyrocketed by 99bps to 105.12% in 2024, then surged by 32bps to 71.37% in 2025.
  • The last three reported values for FCF Margin were 71.37% (Q4 2025), 132.69% (Q3 2025), and 124.95% (Q2 2025) per Business Quant data.